Quarterly ResultMay 12, 2026, 04:13 PM
Relmada Therapeutics Cash & Investments Soar to $234M in Q1
AI Summary
Relmada Therapeutics reported a net loss of $(19.1) million for the first quarter of 2026, an increase from $(17.6) million in the prior year period. However, the company significantly strengthened its financial position, with cash and short-term investments soaring to $234.0 million, primarily due to a $150 million private placement in March 2026 and a $94 million offering in November 2025. Research and development expenses decreased year-over-year, while general and administrative expenses rose. The company is focusing on its NDV-01 and sepranolone programs, having terminated the Esmethadone and psilocybin programs.
Key Highlights
- Cash and cash equivalents plus short-term investments increased to $234.0 million as of March 31, 2026.
- Total assets grew to $235.4 million as of March 31, 2026, from $94.0 million at December 31, 2025.
- Net loss for the three months ended March 31, 2026, was $(19.1) million, compared to $(17.6) million in Q1 2025.
- Loss per common share improved to $(0.22) for Q1 2026 from $(0.58) for Q1 2025.
- Research and development expenses decreased to $8.1 million in Q1 2026 from $12.0 million in Q1 2025.
- General and administrative expenses increased to $11.4 million in Q1 2026 from $6.3 million in Q1 2025.
- Net cash provided by financing activities was $156.6 million for the three months ended March 31, 2026.
- Management believes existing cash and investments will fund operations for at least 12 months.